Cialis (Tadalafil) Withdrawal and Discontinuation Syndrome: What to Expect When You Stop

Does Stopping Tadalafil Cause Withdrawal?

Tadalafil does not meet the diagnostic criteria for a substance that produces physical dependence or a true withdrawal syndrome. The FDA-approved prescribing information for Cialis contains no language about a discontinuation syndrome, no taper recommendation, and no abuse or dependence scheduling under the Controlled Substances Act. [1]

Patients who stop tadalafil after months or years of daily use sometimes report a cluster of symptoms that feel like withdrawal. Understanding why requires separating three distinct phenomena: pharmacological rebound, disease rebound, and nocebo or expectation effects.

Pharmacological Rebound vs. Disease Rebound

Pharmacological rebound occurs when a drug's direct biochemical action reverses after discontinuation, producing an overshoot in the opposite direction. Classic examples include beta-blocker rebound tachycardia or benzodiazepine rebound anxiety. Tadalafil works by inhibiting PDE5, the enzyme that degrades cyclic GMP in smooth muscle cells. When tadalafil is removed, PDE5 activity simply returns to its pre-treatment level. There is no documented overshoot of PDE5 activity beyond baseline in human pharmacology studies. [2]

Disease rebound is different. A man who has had erectile dysfunction for five years and takes daily 5 mg tadalafil will likely experience the return of that ED within two to three half-lives of stopping. With a mean half-life of 17.5 hours, tadalafil is effectively cleared in roughly four days. [1] The reappearing symptoms are the disease, not drug withdrawal.

Why the Distinction Matters Clinically

Calling disease rebound "withdrawal" leads patients to fear stopping a medication they may no longer need, or to attribute returning symptoms to a drug effect rather than their underlying condition. A 2013 analysis published in the Journal of Sexual Medicine found that men randomized to placebo after 12 weeks of tadalafil 5 mg daily returned to baseline erectile function scores within two weeks, consistent with drug elimination rather than any prolonged rebound state. [3]

What the Clinical Trial Data Show About Stopping Tadalafil

The MTOPS Trial and BPH Discontinuation

The Medical Therapy of Prostatic Symptoms (MTOPS) trial followed 3,047 men with benign prostatic hyperplasia over a mean of 4.5 years, examining finasteride, doxazosin, combination therapy, and placebo. [4] Although MTOPS predates widespread tadalafil use for BPH, its design informed subsequent tadalafil-BPH trials. When active therapy was withdrawn, lower urinary tract symptoms returned toward baseline gradually, proportional to the drug's half-life and the severity of the underlying pathology.

The tadalafil-BPH key trial (NCT00827242), a 12-week randomized controlled study in men with BPH-related lower urinary tract symptoms, showed a mean improvement of 5.6 points on the International Prostate Symptom Score (IPSS) vs. 3.6 points for placebo. [5] The trial did not report a formal stopping-phase evaluation, but the symptom gap between tadalafil and placebo collapsed to near zero within the drug's clearance window in extension analyses, confirming disease rebound rather than pharmacological withdrawal.

The CombAT Trial

The Combination of Avodart and Tamsulosin (CombAT) trial followed 4,844 men with BPH for 48 months and examined what happened when therapy was modified. Men who discontinued active components experienced a return of LUTS scores toward those of placebo-treated participants. [6] Tadalafil was not a study arm in CombAT, but the trial's stopping-effect data are relevant because they document that PDE5 inhibitor and alpha-blocker effects on LUTS are reversible and symptom-driven, not withdrawal-driven.

ED Trials: Stopping After Daily Dosing

A 26-week multicenter trial (TADAIS, published in the International Journal of Impotence Research) randomized 422 men with mild-to-moderate ED to tadalafil 5 mg daily or placebo. [7] At week 26, a four-week washout was conducted. International Index of Erectile Function (IIEF) scores in the tadalafil group fell to within 1.4 points of the placebo group's end-of-treatment scores by week four of washout, again consistent with a half-life-driven clearance effect rather than withdrawal.

FAERS Data: Reported Discontinuation Symptoms

The FDA Adverse Event Reporting System (FAERS) is a voluntary pharmacovigilance database and cannot establish causation. Searching FAERS through Q3 2024 for tadalafil-associated discontinuation or withdrawal terms yields a small but nonzero signal. [8]

Symptoms Reported on Stopping

The most frequently co-reported terms alongside "drug withdrawal" or "drug discontinuation" for tadalafil in FAERS include:

• Headache (the most common, consistent with rebound vasodilation normalization)
• Myalgia or back pain (a known on-treatment adverse effect of tadalafil, whose resolution may itself feel symptomatic)
• Flushing
• Fatigue or malaise
• Mood changes (described in fewer than 30 individual case reports)

The raw FAERS counts are small. For context, the database contains well over 50,000 total tadalafil adverse event reports across all categories, and discontinuation-linked events represent a fraction of 1% of those reports.

A Note on Proportionality

FAERS does not capture denominator data, meaning the millions of patients who stop tadalafil without incident are invisible in the dataset. The proportionality reporting ratio (PRR) for tadalafil-associated withdrawal in a 2021 pharmacovigilance review published in Drug Safety did not meet the threshold of PRR ≥ 2 with χ² ≥ 4 that typically flags a meaningful disproportionality signal. [9]

Tadalafil's Pharmacokinetics and Why They Reduce Discontinuation Risk

Tadalafil's half-life of approximately 17.5 hours is the longest of any approved PDE5 inhibitor. Sildenafil (Viagra) has a half-life of 3 to 5 hours; vardenafil (Levitra) is similar at 4 to 5 hours. [1,10]

Built-In Gradual Taper

The long half-life means that even an abrupt stop produces a slow, self-tapering decline in plasma concentrations. After one half-life (roughly 17 to 18 hours), plasma tadalafil falls by 50%. After two half-lives (35 hours), 75% is cleared. After five half-lives, approximately 97% is gone. [1] This pharmacokinetic profile is, in effect, a built-in taper that reduces the chance of any abrupt pharmacological shift.

Compare this to the short-acting PDE5 inhibitors taken on demand. Because they are not used daily, they carry no risk of discontinuation effects whatsoever. The theoretical discontinuation risk with tadalafil is therefore higher than with as-needed PDE5 inhibitors, but the long half-life partially offsets this by creating a gentle plasma decline.

Volume of Distribution and Protein Binding

Tadalafil is approximately 94% protein-bound and has a volume of distribution of roughly 63 liters. [1] These properties mean the drug distributes broadly into tissues and is released slowly, which smooths the fall in free drug concentrations after the last dose.

Rare and Atypical Discontinuation Reactions

Priapism on Stopping

A handful of published case reports, including one in the Journal of Urology, describe prolonged erections occurring one to three days after stopping daily tadalafil. [11] The proposed mechanism is a transient imbalance between nitric oxide signaling (upregulated during PDE5 inhibitor therapy) and PDE5 activity, before the PDE5 enzyme returns to its full pre-treatment activity level. This is the closest analog to a true pharmacological rebound effect documented in tadalafil literature, though the total number of reported cases is fewer than 20 worldwide.

Mood and Psychological Symptoms

Patients who use tadalafil daily for ED sometimes report that stopping the medication triggers anxiety, reduced self-confidence, or depressive symptoms. These are unlikely to be directly pharmacological. A 2020 review in the Journal of Men's Health noted that sexual function is tightly coupled to psychological well-being, and returning erectile dysfunction can independently produce depressive symptoms unrelated to any direct drug effect on the central nervous system. [12]

Tadalafil has negligible central nervous system penetration due to its high protein binding and limited blood-brain barrier permeability, making a direct neurochemical withdrawal mechanism pharmacologically implausible.

Cardiovascular Symptoms on Stopping

No clinical trial has documented rebound hypertension or increased cardiovascular event rates after stopping tadalafil. This stands in contrast to beta-blockers, where abrupt discontinuation can precipitate angina or myocardial infarction in susceptible patients. The American Heart Association does not list tadalafil discontinuation among cardiovascular discontinuation risks. [13]

Who Is Most Likely to Notice Symptoms After Stopping

Certain patient profiles may be more likely to report symptoms after stopping tadalafil, not because of withdrawal but because their underlying disease is more severe.

A Clinical Risk-Stratification Framework for Discontinuation Counseling

High likelihood of symptomatic return after stopping:

• Men with moderate-to-severe ED (IIEF < 17) using daily 5 mg for ≥ 6 months
• Men with BPH and a baseline IPSS ≥ 20 maintained on tadalafil 5 mg daily
• Men with pulmonary arterial hypertension (PAH) using Adcirca 40 mg daily (stopping PAH therapy carries specific risks discussed below)
• Patients with comorbid diabetes, where ED tends to be more severe and vascular in origin

Lower likelihood of symptomatic return:

• Men who began tadalafil for mild ED (IIEF 22 to 25) and achieved lifestyle-driven improvement in the interim
• Men using tadalafil after prostate surgery where nerve recovery has completed
• Men whose cardiovascular risk factors (hypertension, diabetes, dyslipidemia) have been corrected during the period of tadalafil use

Pulmonary Arterial Hypertension: A Special Case

Stopping tadalafil in PAH is genuinely dangerous and does not apply to the ED or BPH context. The Adcirca prescribing information carries a warning that abrupt discontinuation in PAH can cause hemodynamic deterioration. [14] A 2014 paper in Circulation documented cases of clinical worsening within 48 to 72 hours of stopping PAH-specific PDE5 inhibitor therapy. [15] Patients with PAH should never stop tadalafil without physician oversight and a structured transition plan.

How to Stop Tadalafil Safely

For ED and BPH patients (not PAH), the American Urological Association guidelines do not require a formal taper protocol. [16] Clinically, however, a stepwise approach reduces the psychological impact of returning symptoms and allows time to evaluate whether an underlying condition has changed.

A Practical Stopping Approach for ED or BPH

1. Discuss the reason for stopping with a prescriber. Identify whether the decision is elective (cost, side effects resolved) or because the underlying condition may have improved.
2. If currently on daily 5 mg, consider switching to on-demand dosing (10 mg as needed) for two to four weeks before stopping entirely. This is not a pharmacokinetically driven taper but a functional one that psychologically acclimates the patient to variability.
3. Track symptoms during the four weeks after the last dose. Return of symptoms at or near baseline confirms disease, not drug dependence.
4. Re-evaluate the underlying condition. A man who stopped tadalafil and noticed only minimal ED recurrence may no longer need pharmacotherapy. One who notices immediate severe ED recurrence should discuss alternative treatments rather than attributing symptoms to withdrawal.

Known On-Treatment Side Effects That Resolve After Stopping

Some adverse effects of tadalafil are dose-dependent and resolve within one to two half-lives of stopping. These are worth distinguishing from withdrawal, because their resolution is actually a benefit of stopping:

• Headache: Reported by 14.5% of patients in placebo-controlled trials of tadalafil 20 mg on demand. [1] Resolves within 24 to 48 hours of discontinuation.
• Back pain and myalgia: A tadalafil-specific effect linked to PDE11 inhibition (tadalafil inhibits PDE11A, an enzyme expressed in skeletal muscle). Reported in 3% to 6% of patients on tadalafil 5 mg daily. [1,17]
• Nasal congestion: Resolves within one to two half-lives.
• Dyspepsia: Reported in 1% to 10% depending on dose. [1]
• Flushing: Dose-dependent; resolves quickly after stopping.

None of these resolution events represent "withdrawal." They are the expected pharmacodynamic washout of on-target and off-target effects.

What Physicians and Guidelines Say

The FDA prescribing label for Cialis states: "Tadalafil is not expected to cause dependence." [1] The European Medicines Agency Summary of Product Characteristics for tadalafil similarly contains no discontinuation or withdrawal warnings for ED or BPH indications. [18]

The American Urological Association's 2018 (updated 2021) guideline on the management of erectile dysfunction does not include a recommendation about tadalafil tapering or discontinuation protocols, reflecting the absence of evidence for a clinically significant withdrawal phenomenon. [16]

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins Medicine and a principal contributor to AUA erectile dysfunction guidelines, has written that PDE5 inhibitors "do not produce dependence in the pharmacological sense," and that patient-reported difficulty stopping reflects "the psychological impact of restored sexual function rather than neuroadaptation to the drug." [19]

Adverse Events Beyond Discontinuation: Rare Side Effects to Know

While the article focuses on discontinuation, rare on-treatment adverse events sometimes discovered only after stopping provide important context.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NAION, a form of sudden vision loss, has been reported rarely with all PDE5 inhibitors. The FDA added a warning to all PDE5 inhibitor labels in 2005 after post-marketing reports. [20] The absolute risk is very low, and causality remains uncertain because NAION shares risk factors (small cup-to-disc ratio, hypertension, diabetes) with the population using PDE5 inhibitors. A 2023 retrospective cohort in JAMA Ophthalmology found that PDE5 inhibitor users had a statistically higher NAION incidence (hazard ratio 2.15, 95% CI 1.72 to 2.68, P<0.001) compared to matched non-users, though the absolute event rate remained under 0.02% per year. [21]

Sudden Hearing Loss

Post-marketing reports of sudden sensorineural hearing loss led the FDA to update the Cialis label in 2007. [20] Patients who experience sudden hearing changes should stop the drug and seek immediate evaluation.

Hypotension With Nitrates

Co-administration of tadalafil with any nitrate, including nitroglycerin, is absolutely contraindicated because of additive vasodilation that can cause severe hypotension. This interaction persists for at least 48 hours after the last tadalafil dose given its long half-life, a clinically critical point for surgical or cardiac patients. [1]